Leukemia & Lymphoma

Article	Citations
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study	81
Impact of SF3B1 mutation in myelofibrosis	42
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma	41
CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia	35
Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant	32
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia	31
CD69 marks a subpopulation of acute myeloid leukemia with enhanced colony forming capacity and a unique signaling activation state	24
Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis	24
Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma	24
The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review	24
High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination	23
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents	23
Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia	22
Indolent B-cell non-Hodgkin lymphomas in children: high association with inborn errors of immunity	22
Correction	22
Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia	21
Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study	21
Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis	21
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma	21
Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia	20
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma	20
Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy	19
Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax	19
MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma	19
New therapies for angioimmunoblastic T-cell lymphoma: a comprehensive review and analysis	18

Cigarette smoking is associated with worse prognosis in myelodysplastic syndromes and hematopoietic alterations in murine models	18
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy	17
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports	17
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clini	17
The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis	17
Management of relapsed/refractory mantle cell lymphoma	17
Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF)	16
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation	16
Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma	16
Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL)	16
Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma	16
Improvement in mortality of hospitalized patients with hematological malignancies in the 2nd wave of COVID-19 in the UK: experience of a large London NHS trust	16
Transplantation provides superior survival high risk myeloid malignancies in older patients	15
Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes	14
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma	14
Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management	14
XX International workshop on chronic lymphocytic leukemia	14
Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study	14
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study	13
Organ toxicities associated with chimeric antigen receptor T-cell therapy	13
Rare HNRNPH1::ERG rearrangement in a case of de novo pediatric AML and review of cases	13
Making the case for the case report – informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients	13
Serum lipid trajectories in the years before a lymphoma diagnosis	13
Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim 18 F-FDG PET/CT scans	13
Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?	13
Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor – a retrospective, single center study	13
Trametinib enhances ATRA-induced differentiation in AML cells	12
Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplanta	12
Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine	12
Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma	12
Interferon maintenance for prevention of relapse in favorable risk AML?	12
CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors	12
Richter transformation – retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group	12
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma	12
MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratification	12
Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease	12
Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases	12
Infections in secondary immunodeficiency patients treated with Privigen®or Hizentra®: a retrospective US administrative claims study in patients with hematological malignancies	12
A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma	12
Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic	11
Evaluation of non-research and research industry payments to pediatric hematologist/oncologists in the United States between 2013 and 2021	11
State-wise disparities and temporal trends in acute myeloid leukemia (AML) in the United States of America (USA)	11
Progressive eosinophilia and STAT5B mutation acquisition in AML treated with azacitidine and venetoclax	11
Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS	11
Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma	11
PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of BCR-ABL1 -like acute lymphoblastic leukaemia in Indian patients	11
Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience	11
Chemotherapy-free approach with arsenic trioxide and all-trans retinoic acid in children with acute promyelocytic leukemia	11
CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges	11
Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study	11

Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice	10
Correction	10
NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma—opportunities for therapy	10
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison	10
Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab	10
The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics	10
Targeting mitochondrial metabolism in acute myeloid leukemia	10
Megakaryocyte centrosomal and Golgi structural perturbations in patients with primary myelofibrosis and with RUNX1 germline mutation	10
Prephase steroid use and association with dose delays and outcomes in a real-world cohort of older adults treated for diffuse large B-cell lymphoma	10
[ 211 At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies	10
Two recurrent types of IGH ::5′ BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the	10
Impact of chronic graft- versus -host disease on non-relapse mortality and survival	10
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome	10
Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression	10
The International Prognostic Score and HIV status predict red cell concentrate transfusion needs in Hodgkin lymphoma	10
A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma	10
Intake of benzodiazepines in treatment naïve chronic lymphocytic leukemia patients is associate with a shorter time to first treatment	9
A single-center analysis of patients with extranodal marginal zone lymphoma of the breast	9
Sun protection behaviors among adult survivors receiving hematopoietic cell transplantation: a cross-sectional survey of a single institution in Japan	9
The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma	9
A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse	9
Well-differentiated systemic mastocytosis with associated myeloid sarcoma and myelodysplastic syndrome: Diagnostic challenges of an underrecognized entity	9
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas	9
Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia	9
Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir	9
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma	9
Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy	9
Prediction for sustained deep molecular response for treatment-free remission	9
Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma	9
COVID-19 antibody titers after tixagevimab–cilgavimab injection in patients with hematologic diseases; a single-center, prospective study	9
Low-risk relapsed acute lymphoblastic leukemia in children and young adults: what have we learnt and what’s next?	9
Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia	9
MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis	9
Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation	9
Prospects for liquid biopsy approaches in lymphomas	9
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia	9
Achievement of durable remission of relapsed/refractory acute myeloid leukemia in a child using venetoclax monotherapy	9
Effectiveness and safety of leukapheresis in hyperleukocytic leukemias: a retrospective multicenter study	9
Lymphocyte HLA-DR/CD-38 co-expression correlates with Hodgkin lymphoma cell cytotoxicity in vitro independent of PD-1/PD1-L pathway	9
Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenome	9
Off-label use of recombinant activated factor VII in hemophagocytic lymphohistiocytosis patients with major bleeding	9
The diagnosis of Burkitt lymphoma: how do pathologists apply criteria in daily practice?	9
Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression	9
Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial	8
White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia	8
Familial aspects of multiple myeloma and Waldenström macroglobulinemia: understanding the predisposition in relatives and the importance of early diagnosis	8
TP53 -altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs	8
Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy – a retrospective cohort stud	8
Role of the splenic microenvironment in chronic lymphocytic leukemia development in Eµ-TCL1 transgenic mice	8
Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients	8
CALR -mutated myeloproliferative neoplasms	8
Emerging drug profile: JAK inhibitors	8
Clinical and molecular characterization of myeloid sarcoma without medullary leukemia	8
Fatigue – a substantial problem in hematology, but what can be done?	8
Unmanipulated haploidentical donor and matched unrelated donor hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: a single-center study	8
The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia	8
Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients	8
Ixazomib-induced thrombotic microangiopathy resolving without complement pathway inhibition: a case report	8
Effects of fludarabine dosage on transplant-related outcomes in hematopoietic stem cell transplantation	8
Clinical characteristics and outcomes of Brazilian patients with duodenal-type follicular lymphoma: a multicenter retrospective study	8
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia	8
Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen	8
The diagnostic profile of rare acute myelomegakaryoblastic leukemia	8
Genomic landscape of T-large granular lymphocyte leukemia and chronic lymphoproliferative disorder of NK cells: a single institution experience	7
Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission	7
Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation	7
Evaluation of a safe neutrophil count for cessation of intravenous antibiotics and early hospital discharge in stable, afebrile patients recovering after acute myeloid leukemia therapy or an autograft	7
Correction	7
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin ( NPM1 ) gene mutation subtypes: a single-center experience and re	7
Successful treatment of acquired von Willebrand syndrome secondary to low-grade CLL with rituximab and venetoclax	7
Anticipation in hematopoietic malignancies: biology, bias, or both?	7
Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin	7
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma	7
Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas	7
Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation	7
Response to trametinib of two pediatric myeloid malignancies cases harboring RAS mutation and monosomy 7	7
A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantation	7
Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the ‘RTL’ (regional Tuscan lymphoma network)	7
Performance of the frailty index in predicting complete remission, intensive care unit admission, and overall mortality in older and younger patients with acute myeloid leukemia receiving intensive ch	7
Myeloid/lymphoid neoplasm with a novel cryptic RBPMS::FGFR1 rearrangement presenting as de novo acute leukemias	7

Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era	7
Inter-racial genetic differences in myelofibrosis: a diverse inner-city center analysis	7
CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases	7
HHV8-Negative Effusion-Based lymphoma in a patient with recurrent HCV hepatitis status post liver transplantation	7
Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study	7
Graft failure after “ex-vivo” T-cell depleted haploidentical transplantation in pediatric patients with high-risk hematological malignancies. A risk factors and outcomes analysis	7
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach	7
Leukocytosis and MPNs: Where do we stand?	7
Progressive TP53 inactivation in an aggressive splenic diffuse red pulp small B-cell lymphoma	7
Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era – forgotten but not gone	7
CD5- B-cell lymphocytic leukemia –a diagnostic exclusion of splenic B-cell leukemia with prominent nuclei challenging current international consensus	7
Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia	7
Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis	7
A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia	7
Optimizing pegaspargase therapy in patients with hypersensitivity reactions	7
The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study	7
Prevalence and clinicopathological features of incidentally detected TRBC1-dim populations in peripheral blood flow cytometry	7
Mitigating time toxicity in lymphoma and multiple myeloma	7
Patterns of care and outcomes of early stage I–II Hodgkin lymphoma treated with or without radiation therapy	6
Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma	6
A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma	6
Novel treatment for mantle cell lymphoma – impact of BTK inhibitors and beyond	6
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor	6
Nivolumab in refractory cerebral relapse of Hodgkin’s lymphoma	6
Lower intensity regimens for acute myeloid leukemia: opportunities and challenges	6
Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive	6
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma	6
Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma	6
Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function	6
Allogeneic transplant graft source – conditioning – GVHD prophylaxis: don’t mix and match!	6
Follicular lymphoma of the lower female genital tract: an indolent and localized extranodal follicular lymphoma with mutation of TNFRSF14	6
Mean platelet volume may not be a predictive and prognostic marker in patients with acute myeloid leukemia	6
Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance	6
Polymerase chain reaction in the diagnosis of invasive aspergillosis: approaches for appropriate use	6
Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry	6
Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma	6
Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study	6
Labile CD22 and CD19 expression in a case of Philadelphia chromosome-like acute lymphoblastic leukemia	6
Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment	6
Distinct immune-response profile of Richter transformation chronic lymphocytic leukemia (CLL), defined by high expression of PD1, LAG3, TIM3 and IL-10	6
Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3	6
Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation	6
Consistency of the efficacy of immunotherapy with histamine dihydrochloride and low-dose interleukin-2 for relapse prevention in acute myeloid leukemia	6
Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation	6
Tagraxofusp as first-line treatment for blastic plasmacytoid dendritic cell neoplasm	6
Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma	6
COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies	6
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults	6
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma	6
A novel ETV6::FGFR1 fusion gene in a myeloid/lymphoid neoplasm with FGFR1 rearrangement sensitive to specific FGFR1-2-3	6
The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing	6
Central nervous system (CNS) involvement has an adverse impact on survival in newly diagnosed adult acute lymphoblastic leukemia (ALL) assessed by flow cytometry	6
Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey	6
Correction	6
Epstein-Barr virus copy number in peripheral blood mononuclear cells predicts prognosis in diffuse large B cell lymphoma	6
Hepatic Veno-occlusive disease (VOD) in multiple myeloma patient receiving Belantamab Mafodotin	6
A case of testicular diffuse large B-cell lymphoma with late relapse in the skin: the critical role of comparative phenotypic, clonality, and cytogenetic testing	6
Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group	6
Promising activity of single agent nivolumab followed by low-dose whole brain radiotherapy in isolated central nervous system relapse of Hodgkin lymphoma	6
Normal and malignant cells are homogeneously distributed in the bone marrow of children	6
A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome	6
Risk factors for influenza virus infection in patients with hematological disease	5
The pretreatment Controlling Nutritional Status score is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma	5
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia	5
Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination	5
Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma	5
Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype	5
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)	5
Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies	5
Validation of SAPS 3 for predicting in-hospital mortality in patients with haematological malignancy requiring ICU management	5
Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada	5
Consecutive day dosing of high-dose cytarabine consolidation over 3 days is resource-efficient and safe in older adult patients with acute myeloid leukemia	5
Elicitation of societal preferences for chronic lymphocytic leukemia’s treatments: a discrete choice experiment	5
Response to ‘blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives’	5
Attempted desensitization to calaspargase pegol: a familiar approach to a new problem	5
TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression	5
Treatment of relapsed and refractory Waldenstrom Macroglobulinemia	5
The challenge of non-transplant eligible, newly diagnosed multiple myeloma	5
RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL	5
Race (and ethnicity) matters in myelodysplastic syndromes	5
Be on guard: longer monitoring for very–late onset hepatitis B virus reactivation after chemo-immunotherapy?	5
The diverse landscape of fusion transcripts in 25 different hematological entities	5
Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of TP53 mutation and genetic complexity	5
Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data	5
Therapeutic approaches for the management of higher risk myelodysplastic syndromes	5
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data	5
COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study	5
Identification and genetic characterization of a NUP98-HHEX molecular rearrangement in a pediatric acute myeloid leukemia	5
Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis	5
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline ‘chemotherapy-free’ therapy	5
Prognostic factors and outcomes of infant acute lymphoblastic leukemia (ALL), hypodiploid ALL, and mixed-phenotype acute leukemia (MPAL) in Canada: a report from CYP-C	5
Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitor?	5
Persistent parvovirus B19 infection in a heavily pretreated lymphoma patient receiving mosunetuzumab	5
Bone primary, spindle cell variant of diffuse large B-cell lymphoma presenting in the femur from a Paget’s disease patient	5
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant	5